MET-PCOS Trial

Cross-source consensus on MET-PCOS Trial from 1 sources and 5 claims.

1 sources · 5 claims

Comparisons

MET-PCOS is a double-blind randomized controlled trial comparing two metformin doses in women with PCOS. — Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial
The trial plans to enroll 184 participants, with 92 participants in each treatment arm. — Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial
As of 19 December 2025, the trial had recruited 10 women with PCOS. — Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial
Participants must be adults aged 18-37 years with BMI from at least 25 to under 40 kg/m2 and meet the 2023 Rotterdam criteria for PCOS. — Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial
Recruitment began in October 2025, and the first participant entered the study in November 2025. — Optimising metformin use in polycystic ovary syndrome (MET-PCOS): study protocol for a double-blind randomised controlled trial